- Home
- WFRD vs PCVX Comparison
WFRD vs PCVX Comparison
Compare WFRD & PCVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WFRD | PCVX |
|---|---|---|
| Founded | 1941 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 6.0B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | WFRD | PCVX |
|---|---|---|
| Price | $80.60 | $48.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 7 |
| Target Price | $93.22 | ★ $101.67 |
| AVG Volume (30 Days) | 913.1K | ★ 1.5M |
| Earning Date | 02-03-2026 | 11-04-2025 |
| Dividend Yield | ★ 1.27% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.52 | N/A |
| Revenue | ★ $4,970,000,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.28 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $36.74 | $27.66 |
| 52 Week High | $82.26 | $93.77 |
Technical Indicators
Market Signals| Indicator | WFRD | PCVX |
|---|---|---|
| Relative Strength Index (RSI) | 61.85 | 59.27 |
| Support Level | $75.23 | $42.40 |
| Resistance Level | $82.26 | $45.15 |
| Average True Range (ATR) | 2.19 | 1.94 |
| MACD | -0.12 | -0.02 |
| Stochastic Oscillator | 76.84 | 91.30 |
Price Performance
Historical ComparisonAbout WFRD Weatherford International plc
Weatherford International provides diversified oilfield services across international markets for an array of oilfield types. The firm is a global market leader in artificial lift and tubular running services. Other key product lines include cementing products, directional drilling, and wireline evaluation.
About PCVX Vaxcyte Inc.
Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.